| Experimental groups |
Time of administration [days] |
Cardiomyopathy N [%] |
| Sham-operated (n=10) |
- |
0 |
| 21 to 28 day after MI |
| 0.9% NaCl (n=8) |
8 |
8 [100%] |
| 0.4% DMSO (n=6) |
8 |
1 [16%]* |
| M-2 (n=14) |
8 |
1 [7%]* |
| 21 to 35 day after MI |
| 0.9% NaCl (n=8) |
15 |
3 [38%] |
| 0.4% DMSO (n=6) |
15 |
1 [16%] |
| M-2 (n=14) |
15 |
2 [14%] |
| 11 to 28 day after MI |
| 0.9% NaCl (n=8) |
18 |
8 [100%] |
| 0.4% DMSO (n=6) |
18 |
3 [50%] |
| M-2 (n=14) |
18 |
0*# |
| 11 to 35 day after MI |
| 0.9% NaCl (n=8) |
25 |
3 [38%] |
| 0.4% DMSO (n=6) |
25 |
3 [50%] |
| M-2 (n=12) |
25 |
0*# |
| 6 to 35 day after MI |
| 0.9% NaCl (n=8) |
30 |
3 [38%] |
| 0.4% DMSO (n=6) |
30 |
3 [50%] |
| M-2 (n=10) |
30 |
0*# |
The chi-square-test (χ2 Yates) was used to estimate the significance between the incidences of cardiomyopathy development in all comparisons. In all cases differences
were considered significant at P<0.05; n – number of animals/hearts; N – hearts with cardiomyopathy.
*P<0.05 vs. 0.9% NaCl; #P<0.05 vs. 0.4% DMSO. |
